FREQ News and Press, Frequency Therapeutics Inc. From 10/27/21

At Nov. 9 Event, Management and Key Opinion Leaders to Review Detailed FX-322 Clinical Study Results in Patients with Sensorineural Hearing Loss (SNHL) and Design of New FX-322-208 Phase 2b Study Company to Introduce a Second Hearing Restoration Program with a Differentiated B...

FX-322-208 is a Randomized, Placebo-Controlled Study to Evaluate Hearing Improvement in Subjects with Acquired SNHL Company to Host R&D Event on November 9th to Provide Detailed Review of Completed FX-322 Clinical Studies Supporting FX-322-208 Inclusion Criteria and Study ...

In Follow-Up to Phase 1b Learning Study (FX-322-111), Some Subjects with Sensorineural Hearing Loss Show Increased Speech Perception Up to Twelve Months After Dosing Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on develo...

New York, New York--(Newsfile Corp. - August 12, 2021) -  Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating potential claims involving directors and officers regarding possible breaches of fiduciary duties related to whether insiders caused their companies ...

Company Plans to Commence New FX-322 Phase 2 Study in Q4 2021 in a Refined Population of Individuals with Sensorineural Hearing Loss (SNHL) Will Host R&D Event on November 9 th to Provide Detailed Insights into FX-322 Clinical Data, Plans for Continued FX-322 Developme...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency Therapeutics To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 17, 2021) - Faruqi & Faruqi, LLP, a leading national securitie...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency Therapeutics To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 15, 2021) - Faruqi & Faruqi, LLP, a leading national securitie...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Frequency Therapeutics To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 12, 2021) -  Faruqi & Faruqi, LLP, a leading national sec...

Decibel is a category leader in developing new medicines for hearing and balance disorders. The company's lead asset, DB-OTO, has several upcoming catalysts over the next 18 months that can validate Decibel's platform. With a unique business model, Decibel is a compelling investme...

Companies engaged in developing therapies for Alzheimer's disease were among the best performing biotech stocks in the first half of the year.Cassava Sciences ([[SAVA]] -1.7%) was the best performing biotech stock in the half, with a return in the period of 1166%.A phase 3 trial of its Alzhei...